Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 642.25

-1.5%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioBait	2/15/2022 8:14:16 AM
	Read Replies (1) of 3557

Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 As far as I can tell, Lilly got a quick eua compared to previous eua. Maybe regeneron will get some revenue for its new cocktail in 2022? That would be a nice bonus. A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4) NCT04634409

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next